Substrate Specificity of the Oncoprotein v-Fps:  Site-Specific Mutagenesis of the Putative P+1 Pocket†

Biochemistry ◽  
2000 ◽  
Vol 39 (1) ◽  
pp. 255-262 ◽  
Author(s):  
Laurel Konkol ◽  
T. John Hirai ◽  
Joseph A. Adams
FEBS Letters ◽  
1994 ◽  
Vol 355 (3) ◽  
pp. 271-274 ◽  
Author(s):  
Michiro Muraki ◽  
Yoshifumi Jigami ◽  
Kazuaki Harata

Biochemistry ◽  
2001 ◽  
Vol 40 (51) ◽  
pp. 15464-15470 ◽  
Author(s):  
Christopher D. Reeves ◽  
Sumati Murli ◽  
Gary W. Ashley ◽  
Misty Piagentini ◽  
C. Richard Hutchinson ◽  
...  

2000 ◽  
Vol 284 (1) ◽  
pp. 42-48 ◽  
Author(s):  
Sung Yun Kim ◽  
Kye Won Park ◽  
Yong Jae Lee ◽  
Sung Hoon Back ◽  
Jae Hwan Goo ◽  
...  

2013 ◽  
Vol 47 (6) ◽  
pp. 784-795 ◽  
Author(s):  
E. V. Zemlyanskaya ◽  
S. Kh. Degtyarev

1997 ◽  
Vol 272 (3) ◽  
pp. 1601-1607 ◽  
Author(s):  
Misa Inohara-Ochiai ◽  
Toru Nakayama ◽  
Rieko Goto ◽  
Masahiro Nakao ◽  
Takashi Ueda ◽  
...  

2018 ◽  
Vol 12 (1) ◽  
pp. 111-123 ◽  
Author(s):  
Abhinav P. Mishra ◽  
Suresh Chandra ◽  
Ruchi Tiwari ◽  
Ashish Srivastava ◽  
Gaurav Tiwari

In designing of Prodrugs, targeting can be achieved in two ways: site-specified drug delivery and site-specific drug bioactivation. Prodrugs can be designed to target specific enzymes or carriers by considering enzyme-substrate specificity or carrier-substrate specificity in order to overcome various undesirable drug properties. There are certain techniques which are used for tumor targeting such as Antibody Directed Enzyme Prodrug Therapy [ADEPT] Gene-Directed Enzyme Prodrug Therapy [GDEPT], Virus Directed Enzyme Prodrug Therapy [VDEPT] and Gene Prodrug Activation Therapy [GPAT]. Our review focuses on the Prodrugs used in site-specific drug delivery system specially on tumor targeting.


Sign in / Sign up

Export Citation Format

Share Document